Calamos Advisors
MACK

Calamos Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Calamos Advisors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-7,359
Closed -$220K – 662
2013
Q3 		$220K Buy
+7,359
New +$257K ﹤0.01% 589

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Calamos Advisors's MACK Position: Q4 2013 in Review

Calamos Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2013, closing a stake of 7,359 shares — an estimated $220K sold.

Calamos Advisors first reported a position in MACK in Q3 2013 and held it in 1 quarter. The position peaked at $220K in Q3 2013. 93 funds tracked by Wall St. Rank hold MACK as of Q4 2013.

  • Calamos Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2013 after selling out during the quarter.
  • Calamos Advisors sold 7,359 Merrimack Pharmaceuticals, Inc. shares in Q4 2013, an estimated $220K.
  • Calamos Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2013 and held it in 1 quarter.
  • Calamos Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $220K in Q3 2013.
  • 93 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2013.

Based on Calamos Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.